Author
Andrea Flesken‐Nikitin
Cornell UniversityORCID 0000-0003-3017-1399Unclaimed ORCID profile · follow to get notified of new preprints
Biology Disciplines
Click to filter author papersSignature Assays, Organisms & Methods
Click to filter · or open tagActivity by Year
2025-2026 · peak 3/yrCo-Author Collaboration Network
10 top collaborators · 41 mutual co-author links5 papers
Recent·Most cited
- Cancer BiologyCancer Heterogeneity and PlasticityPeer-reviewed
Keratin 5 marks cancer-propagating cells sustained by an osteopontin-producing niche in high-grade serous ovarian carcinoma
Mallikarjun Bidarimath, Coulter Q. Ralston, Nandini Bidarimath…·Alexander Yu. Nikitin
This study identifies KRT5-expressing cells as cancer-propagating cells in HGSC that depend on an OPN-producing niche for survival and chemoresistance.
2 citationstop 4% - Cancer BiologybioRxivPreprint
Comparative single-cell atlases reveal injury-driven tubal epithelial regeneration as a window for ovarian carcinoma initiation
Coulter Q. Ralston, Andrea Flesken‐Nikitin, Dah‐Jiun Fu…·Alexander Yu. Nikitin
The paper compares single-cell transcriptomes of mouse and human tubal epithelium to show injury-driven regeneration in humans may contribute to ovarian cancer initiation.
- Cancer BiologyThe Journal of PathologyPeer-reviewed
Dysregulation of cell state dynamics during early stages of serous endometrial carcinogenesis
Andrea Flesken‐Nikitin, Matalin G. Pirtz, Christopher S. Ashe…·Alexander Yu. Nikitin
This study identifies 44 genes, including novel markers like OAS2 and OASL, as potential early diagnostic and prognostic markers for serous endometrial carcinoma using a mouse model and multi-omics approaches.
- Cancer BiologybioRxivPreprint
Combinatorial organoid mutagenesis screen reveals gene constellations driving malignant transformation, pathology and chemosensitivity in high-grade serous ovarian carcinoma
Daryl J. Phuong, Coulter Q. Ralston, Tamer Ezzat…·John C. Schimenti
This study uses combinatorial CRISPR mutagenesis in organoids to identify gene combinations driving malignant transformation, pathology, and chemosensitivity in high-grade serous ovarian carcinoma.